Category: Marburg Virus
(WHO) The WHO R&D Blueprint is organizing an urgent meeting with the MARVAC partners to discuss vaccine and therapeutic candidates. We will convene an urgent meeting to outline proposed research priorities towards the newly identified Marburg outbreak in Equatorial Guinea. Agenda 1- Outbreak sit rep including diagnostics and epi info2- Review of core trial protocol (Ira Longini)3- Review […]
Feb 13, 2023
New Marburg Virus Outbreak Confirmed In Equatorial Guinea
(Forbes) Equatorial Guinea has just confirmed its first outbreak of Marburg virus, one of the families of hemorrhagic fevers related to Ebola. As with last year’s outbreak in Ghana, patient specimens had to be sent to the Institut Pasteur in Senegal for confirmation, as it requires specialized testing. One of eight samples has been confirmed […]
Feb 13, 2023
Equatorial Guinea declares outbreak of Ebola-like Marburg virus
(BNO News) An illness which has killed at least nine people in Equatorial Guinea has been identified as Marburg, a highly infectious and deadly Ebola-like virus for which there’s no vaccine, officials announced Monday. The outbreak was first detected last Tuesday, affecting people who went to a funeral ceremony in Kie-Ntem province, which borders Cameroon […]
Feb 13, 2023
Marburg vaccine shows promising results in first-in-human study
(NIH) A newly published paper in The Lancet shows that an experimental vaccine against Marburg virus (MARV) was safe and induced an immune response in a small, first-in-human clinical trial. The vaccine, developed by researchers at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, could someday be an important tool […]
Jan 31, 2023
Around 12+ key companies are developing the Marburg Virus Disease Therapies | DelveInsight
Market screener – DelveInsight’s “Marburg Virus Disease Pipeline Insight” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in the Marburg Virus Disease pipeline landscapes. It comprises Marburg Virus Disease pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Marburg Virus Disease therapeutics assessment by product type, stage, route […]
Oct 12, 2022